Significance of Hyperbaric Oxygenation in the Treatment of Fournier’s Gangrene: A Comparative Study by Anheuser, Petra et al.
Original Paper
Urol Int 2018;101:467–471
Significance of Hyperbaric Oxygenation 
in the Treatment of Fournier’s Gangrene: 
A Comparative Study
Petra Anheuser a    Sandra Mühlstädt b    Jennifer Kranz c    Laila Schneidewind d    
Joachim Steffens c    Paolo Fornara b    
a
 Department of Urology, Asklepios Clinic St. Georg, Hamburg, Germany; b Department of Urology and Kidney 
Transplantation, Martin Luther University, Halle, Germany; c Department of Urology and Pediatric Urology, St. 
Antonius Hospital, Eschweiler, Germany; d Department of Internal Medicine, University Medicine Greifswald, 
Hematology-Oncology-Transplant Center, Greifswald, Germany
Received: July 24, 2018
Accepted: September 12, 2018
Published online: October 16, 2018
Internationalis
Urologia
Petra Anheuser, MD
Department of Urology
Asklepios Clinic St. Georg
Lohmühlenstrasse 5, DE–22009 Hamburg (Germany)
E-Mail petra.anheuser @ web.de
Sandra Mühlstädt, MD
Department of Urology and Kidney Transplantation
Martin Luther University
Ernst-Grube-Strasse 40, DE–06120 Halle (Saale) (Germany)
E-Mail sandra.muehlstaedt @ uk-halle.de
© 2018 S. Karger AG, Basel
E-Mail karger@karger.com
www.karger.com/uin
DOI: 10.1159/000493898
Keywords
Necrotizing fasciitis · Fournier’s gangrene · Necrotomy · 
Soft tissue infection · Hyperbaric oxygenation
Abstract
Introduction: Hyperbaric oxygenation (HBO), in addition to 
anti-infective and surgical therapy, seems to be a key treat-
ment point for Fournier’s gangrene. The aim of this study 
was to investigate the influence of HBO therapy on the out-
come and prognosis of Fournier’s gangrene. Patients and 
Methods: In the present multicenter, retrospective observa-
tional study, we evaluated the data of approximately 62 pa-
tients diagnosed with Fournier’s gangrene between 2007 
and 2017. For comparison, 2 groups were distinguished: pa-
tients without HBO therapy (group A, n = 45) and patients 
with HBO therapy (group B, n = 17). The analysis included 
sex, age, comorbidities, clinical symptoms, laboratory and 
microbiological data, debridement frequency, wound dress-
ing, antibiotic use, outcome and prognosis. The statistical 
analysis was performed with GraphPad Prism 7® (GraphPad 
Software, Inc., La Jolla, USA). Results: Demographic data 
showed no significant differences. The laboratory parame-
ters C-reactive protein and urea were significantly higher in 
group B (group B: 301.7 vs. 140.6 mg/dL; group A: 124.8 vs. 
54.7 mg/dL). Sepsis criteria were fulfilled in 77.8 and 100% of 
the patients in groups A and B respectively. Treatment in the 
intensive care unit (ICU) was therefore indicated in 69% of 
the patients in group A and 100% of the patients in group B. 
The mean ICU stay was 9 and 32 days for patients in groups 
A and B respectively. The wound debridement frequency 
and hospitalization stay were significantly greater in group 
B (13 vs. 5 debridement and 40 vs. 22 days). Initial antibiosis 
was test validated in 80% of the patients in group A and 
76.5% of the patients in group B. Mortality was 0% in group 
B and 4.4% in the group A. Conclusion: The positive influ-
ence of HBO on the treatment of Fournier’s gangrene can be 
estimated only from the available data. Despite poorer base-
line findings with comparable risk factors, mortality was 0% 
in the HBO group. The analysis of a larger patient cohort is 
desirable to increase the significance of the results.
© 2018 S. Karger AG, Basel
P.A. and S.M. are co-first authors.
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Introduction
Fournier’s gangrene is defined as necrotizing fasciitis 
of the external genitals (as shown in Figs. 1a, b), which 
usually affects male patients. Fournier’s gangrene is a 
rare and serious disease with high morbidity and mortal-
ity and was first described by Baurienne in 1764. One 
century later, the French venereologist Fournier de-
scribed this condition as a special type of soft tissue in-
fection localized to the scrotum, penis, perineum, and 
anterior abdominal wall [1]. Key points for the successful 
treatment of Fournier’s gangrene are immediate surgical 
debridement accompanied by forced antibiotic therapy 
and, usually, intensive medical management [2–4]. 
Fournier’s gangrene usually causes local tissue hypoxia. 
Hyperbaric oxygen (HBO) therapy has a bactericidal ef-
fect on anaerobic infections. HBO improves tissue perfu-
sion, promotes angiogenesis, increases the oxygen level 
in tissues, and inhibits the production of toxins. There-
fore, HBO therapy is widely used to treat mixed infec-
tions [5, 6].
The aim of the following investigation was to com-
pare differences in clinical parameters, morbidity, mor-
tality, and prognosis between Fournier patients treated 
with or without HBO therapy in consideration of the risk 
factors.
Patients and Methods
In the present multicenter, retrospective observational study 
(Department of Urology, Asklepios Clinic, Hamburg, Germany; 
Department of Urology and Kidney Transplantation, Martin 
Luther University, Halle [Saale], Germany; Department of Urol-
ogy and Paediatric Urology, St. Antonius Hospital, Eschweiler, 
Germany and Department of Internal Medicine, University 
Medicine Greifswald, Hematology-Oncology-Transplant Cen-
ter, Greifswald, Germany), we evaluated the data of approxi-
mately 62 patients diagnosed with Fournier’s gangrene between 
2007 and 2017. We analyzed the following parameters: sex, age, 
comorbidities, clinical symptoms, laboratory and microbiologi-
cal data, debridement frequency, wound dressing, antibiotic use, 
outcome, and prognosis. To compare the efficacy of HBO, the 
patients were divided into 2 groups (group A, without HBO, n = 
45; group B, with HBO, n = 17). Furthermore, the data were 
stratified by outcome. The statistical analysis was performed 
with GraphPad Prism 7® (GraphPad Software, Inc., La Jolla, 
USA). Time-dependent changes between the 2 groups are pre-
sented as the mean ± SD and range and were evaluated by 
the  Man-Whitney U test. Categorical data are presented as 
the count and percentage and were evaluated by the chi-square 
test or Fisher’s exact test. Statistical significance was considered 
at p < 0.05.
Results
Of the 62 patients, 45 (72.6%) were treated with stan-
dard therapy: urgent surgical debridement and parenter-
al broad-spectrum antibiotics (group A, non-HBO). The 
other group, with 17 (27.4%) patients, was additionally 
treated with a hyperbaric procedure (group B, HBO).
There were no significant differences between the 
groups regarding the demographic data or preexisting 
diseases. All patients in both groups were male (Table 1). 
The infection parameters measured in the blood at the 
beginning of the inpatient stay are listed in Table 2. There 
were significantly higher values C-reactive protein values 
(301.7 vs. 140.6 mg/dL) and urea values (124.8 vs. 
54.7  mg/%) in the HBO group than in the non-HBO 
group (p < 0.001). There was a positive trend regarding 
leukocytes (22.9/nL, group B; 17.1/nL, group A; p = 0.06). 
No significant difference was observed concerning 
the  mean level of thrombocytes (225.2/nL, non-HBO; 
270.2/nL, HBO; p > 0.21).
The original points of infection are presented in Table 
3. In most cases, the infection originated in the scrotal, 
perineal, or both regions (33 patients, 73.4%, group A; 15 
patients, 88.2%, group B). There were 5 patients with a 
penile origin of infection (5 patients, 11.1%) in the non-
HBO group, while no patients in the HBO group were 
affected in this way. Only some patients showed a rectal 
(4 patients, 8.9%, non-HBO; 1 patient, 5.9%, HBO), in-
guinal (2 patients, 4.4%, non-HBO), urethral (1 patient, 
5.9%, HBO), or renal (1 patient, 2.2%, non-HBO) origin 
of infection, as shown in Table 3.
There were significant differences in the therapeutic 
parameters and clinical outcomes. The median hospital 
stay was 22.5 days in the non-HBO group and 40.3 days 
in the HBO group (p < 0.008). Treatment in the intensive 
care unit (ICU) was necessary for 31 patients (69%) in 
the non-HBO group and for 17 patients (100%) in the 
HBO group. Furthermore, the ICU stay differed signifi-
cantly between the groups (9 days, non-HBO; 32 days, 
HBO; p < 0.001). A total of 77.8% of the patients in the 
non-HBO group met the sepsis criteria (35 patients), as 
did all 17 patients in the HBO group (p = 0.025). Septic 
shock affected 9 of 45 patients (20%) in the non-HBO 
group and 12 of 17 patients (70.5%) in the HBO group 
(p < 0.001).
In the non-HBO and HBO groups, 80% (36 patients) 
and 76.5% (13 patients) of the patients were administered 
test-appropriate first-line antibiotic (p = 0.680). The inci-
dence of 3MRGN was 13.3% (6/45) in the non-HBO 
group and 17.6% (3/17) in the HBO group (p = 0.347). In 
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this context, there was no difference in the ICU stay be-
tween patients with or without test-appropriate first-line 
antibiotic treatment (p < 0.753). Vacuum therapy (VAC) 
was administered to 18 patients (40%) in the non-HBO 
group and to 16 patients (94%) in the HBO group (p < 
0.001). The number of surgical wound debridement ses-
sions varied significantly between the groups, with an av-
erage of 4.8 (±2.9) debridement sessions in the non-HBO 
group and 13.3 (±6.3) debridement sessions in the HBO 
group (p < 0.001).
Inpatient mortality was 4.5% (2/45) in the non-HBO 
group and 0% in the HBO group (0/17).
Discussion
While HBO therapy is an additional treatment after 
surgical debridement and antibiotic therapy in cases of 
soft tissue infection (potential benefits are shown in 
Fig. 2), the benefits of adjuvant HBO therapy remain con-
troversial for necrotizing fasciitis [7]. Nevertheless, the 
positive effects on soft tissue affected by an infection with 
aerobic, and especially anaerobic bacteria, are well under-
stood [8–10]. There are bactericidal and bacteriostatic ef-
fects of increasing the oxygen supply to the cellular level. 
a b
Fig. 1. a Clinical appearance of Fournier’s gangrene with the involvement of the left groin in an obese pa-
tient; case and photo from the Department of Urology and Pediatric Urology, St. Antonius Hospital, Esch-
weiler,  Germany. b Typical findings of a Fournier’s gangrene with primary scrotal manifestation of the same 
patient.
Table 1. Demographic data and physical conditions of patients
Non-HBO HBO p value
Number of patients 45 17
Mean age 60 58 >0.55
Gender, male, n (%) 45 (100) 17 (100)
BMI 28.4 30.1 >0.73
Diabetes melitus, n (%) 23 (50.0) 9 (52.9) >0.89
Alcoholism, n (%) 14 (31.1) 5 (29.4) >0.89
HIV, n (%) 1 (2.2) 0 (0) >0.67
Colon carcinoma, n (%) 2 (4.4) 1 (5.9) >0.81
HBO, hyperbaric oxygenation; BMI, body mass index.
Table 2. Blood parameters before the beginning of therapy
Non-HBO HBO p value
Leucocytes/nL 17.1 22.9 0.06 
Thrombocytes/nL 225.2 270.2 >0.21
CRP, mg/% 140.6 301.7 <0.001
Urea, mg/% 54.7 124.8 <0.001
HBO, hyperbaric oxygenation.
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Angiogenesis is promoted, and collagen synthesis is dou-
bled; both processes are important for the wound-healing 
process. Furthermore, the production of alpha-toxin is 
reduced, and antibiotic therapy is more effective in the 
presence of higher oxygen concentrations [6]. Neverthe-
less, the use of HBO therapy has not been comprehen-
sively established. The main reason for this fact is its avail-
ability in only a few centers in Germany, leading to the 
prolonged and dangerous transportation of patients who 
are likely septic. Another important factor is the tremen-
dous expense of this treatment, ranging from approxi-
mately 8,000–25,000 EUR per patient, which is not reim-
bursed by health insurance [4].
Additionally, the results of HBO therapy in cases with 
soft tissue infection, such as Fournier’s gangrene, vary in 
the literature. Earlier studies have reported the mortality 
rate to be up to 43% [11]. Recent trials have presented 
better results, with 13% for conventional treatment and 
27% for HBO therapy [5]. In contrast to these data, Piz-
zorno et al. [12] reported approximately 0% mortality 
without HBO therapy, while other studies have reported 
approximately 3 and 9% [13–15]. The mortality rate in 
our series was 4.5% without HBO, with incidences of 
mortality resulting from heart attack and septic shock. 
While no patients in the HBO group died during the 
hospital stay, there was no significant difference in mor-
tality between the groups. The better results in the HBO 
group compared with the results mentioned in the lit-
erature, and the non-HBO group in our series could be 
attributable to the excellent availability of HBO therapy 
and reduced dangerous and onerous transportation of 
patients in poor physical conditions. It is known that a 
delay of 24 h in the initial surgical treatment may lead to 
a tenfold greater mortality rate [3, 4]. Experience is an 
additional important factor affecting mortality in the 
treatment of patients with Fournier’s gangrene: seeing 
more than 1 patient per year had an adjusted 42–84% 
lower mortality rate (p < 0.0001) [15, 16]. Another key 
point for improving patient outcome is the immediate 
start of treatment with a broad antibiotic [2, 18] and in-
tensive care therapy [18–20].
Regarding the poorer physical conditions of patients 
in the HBO group compared to the condition of pa-
Table 3. Clinical parameters of patients
Non-HBO HBO p value
Median days stay 22.5 40.3 <0.008
Number of ICU, n (%) 31 (69) 17 (100) 0.009
Median days ICU 6.13 32 <0.001
Number wound debridements, mean 4.8 13.3 <0.001
VAC, n (%) 18 (40) 16 (94)
First antibiotics appr., n (%) 36 (80) 13 (76.5) 0.680
3-MRGN, n (%) 6 (13.3) 3 (17.6) 0.347
Sepsis (criteria), n (%) 35 (77.8) 17 (100) 0.025
Septic shock, n (%) 9 (20) 12 (70.5) <0.001
Mortalität, % (n) 4.5 (2) 0 (0) 0.204
HBO, hyperbaric oxygenation; ICU, intensive care unit; VAC, vacuum-therapy.
Fig. 2. Granulated wound after necrotomy and hyperbaric oxygen-
ation (HBO) therapy in a patient with Fournier’s gangrene due to a 
necrotizing rectal carcinoma with the involvement of the left groin; 
case and photo from the Department of Urology and Kidney Trans-
plantation, Martin Luther University, Halle (Saale), Germany.
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tients  in the non-HBO group (70.5 vs. 20% with septic 
shock), the inclusion of worse infectious parameters 
could explain the only marginally better results in this 
study [18, 19].
Regarding the total hospital stay (22.5 days non-HBO 
vs. 22.9 days HBO), there was no difference between the 
groups, which highlights the positive impact of HBO 
therapy.
The limitations of this study are the retrospective na-
ture of the data, the heterogeneous patient sample, and 
the multidisciplinary and multicenter approach.
Conclusion
The positive influence of HBO therapy on the treat-
ment of Fournier’s gangrene is going to be difficult to 
measure. This nonrandomized retrospective study pres-
ents opposite findings. Despite poorer baseline findings 
with comparable risk factors, there was a 0% mortality in 
the HBO group. This could be a sign of positive influence 
of the HBO-treatment. In contrast, the mean ICU-stay 
differed significantly in favor of the non-HBO group. 
With this observation, the accelerating effect on tissue re-
generation and general convalescence of HBO-therapy is 
not precisely verifiable. To summarize, there are compa-
rable problems as found in other studies on this subject 
of retrospective nature: Prospective investigations with 
larger patient samples are desirable and necessary to clear 
these findings.
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